Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Eledon Pharmaceuticals (ELDN – Research Report), retaining the price ...

The CD40/CD40 ligand (CD40L) costimulatory system, which amplifies immune responses and can induce inflammation, is believed to have a role in skin manifestations of other autoimmune diseases ...

Instead, the company is hoping to use its CD40L inhibitor drug to do a better job at inhibiting an immune response seen in transplant patients with rejection. Having said that, if it ends up being ...

CHATHAM, N.J., Nov. 13, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical ...

Early research shows the CD40L antibody tegoprubart is able to reduce insulin dependence in patients with type 1 diabetes after islet transplants.

Completed enrollment of Phase 2 BESTOW trial of tegoprubart in kidney transplantation four months ahead of schedule; on track to report topline ...

A newly designed therapy following an islet cell transplant could mean people with type 1 diabetes no longer need to inject ...

糖尿病，尤其是1型糖尿病（T1D），一直是一个困扰全球数百万患者的慢性疾病。许多患者每天需要注射胰岛素来控制血糖水平，这不仅给生活带来了不便，还伴随着一系列潜在的健康风险。那么，有没有可能让这些患者彻底摆脱胰岛素呢？最近的一项研究或许为我们带来了答案。 想象一下，如果有一种方法能够让糖尿病患者不再依赖胰岛素，那将是一个多么令人振奋的消息！近日，Eledon Pharmaceuticals公司公布了 ...

Tonix's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting ...

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular ...

研究发现，cd40l从tfh转移至b淋巴细胞需要持续的cd40信号，并使抗原提呈b淋巴细胞在gc中存活和增殖。 CD40L从T淋巴细胞转移至B淋巴细胞的机制可能 ...

Biogen's Q3 earnings report shows flat growth but highlights its value for risk-tolerant investors in CNS disease treatment.